| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1685 | Dc_ym21 Maleate | Novel inhibitor of menin-MLL interaction |
|
| DCC1686 | Dc_ym25 | Novel inhibitor of menin-MLL interaction |
|
| DCC1687 | Dc_ym26 | Novel inhibitor of menin-MLL interaction |
|
| DCC1688 | Dcat Maleate [57915-90-9] | Inhibitor of N-methyl transferases (NMT), preventing the formation of Parkinson's syndrome neurotoxins via methylation of non-methylated pre-neurotoxins. |
|
| DCC1689 | Dc-bpi-11 | Novel potent BPTF-BRD inhibitor, showing selectivities 100-fold higher than those of other BRD targets, significantly inhibiting leukemia cell proliferation |
|
| DCC1690 | Dc-bpi-7 | Novel potent BPTF-BRD inhibitor, showing selectivities 100-fold higher than those of other BRD targets |
|
| DCC1691 | Dc-cpin734 | Novel potent CBP bromodomain inhibitor with a TR-FRET IC50 value of 19.5 ± 1.1 nM and over 400-fold of selectivity against BRD4 bromodomains |
|
| DCC1692 | Dce_254 | Novel potent EZH2 inhibitor |
|
| DCC1693 | Dce_42 | Novel potent EZH2 inhibitor |
|
| DCC1694 | Dc-ebio | Activator of IK and SK channels |
|
| DCC1695 | Dcg066 | Novel inhibitor of lysine methyltransferase G9a |
|
| DCC1696 | dcg-iv | Highly potent agonist for group II mGlu receptors |
|
| DCC1697 | Dc-k2in212 | Novel potent CDK2 inhibitor with selectivities above 10-fold over CDK1/4/6/7/9/12 above 10-fold, displaying anti-proliferative activity against A2058 melanoma and MV4-11 leukemia cell lines and low toxicity on human normal cell lines, inhibiting CDK2-medi |
|
| DCC1698 | Dcn1-ubc12 Inhibitor Dn-2 | Novel potent and selective DCN1-UBC12 inhibitor for anticardiac fibrotic effects, specifically targetinbg DCN1 at molecular and cellular levels, effectively reversing angiotensin (Ang) II-induced cardiac fibroblast activation |
|
| DCC1699 | Dc-prc2in-01 | Novel PRC2 Inhibitor, Targeting EZH2-EED Interaction |
|
| DCC1700 | Dc-s100 | Novel, Selective Histone Methyltransferase SET7 Inhibitor |
|
| DCC1701 | Dc-s238 | Novel, Potent and Selective Histone Methyltransferase SET7 Inhibitor |
|
| DCC1702 | Dc-s239 | Novel, Potent and Selective Histone Methyltransferase SET7 Inhibitor |
|
| DCC1703 | Dc-teadin02 | Novel potent and selective TEAD autopalmitoylation inhibitor, inhibiting TEADs transcription activity and downstream gene expression |
|
| DCC1704 | Dcz3112 | Novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction |
|
| DCC1705 | Dd-04-015 | Novel selective BTK degrader, demonstrating prolonged pharmacodynamic effects |
|
| DCC1706 | Dd04107 Featured | Novel inhibitor of α-calcitonin gene-related peptide (α-CGRP) exocytotic release from primary sensory neurons, selectively interacting with Synaptotagmin 1 |
|
| DCC1707 | Ddc4002 | First-generation allosteric EGFR inhibitor, binding to the allosteric site of EGFR along with ATP that leads to inhibition of cell proliferation and arrest of EGFR L858R/T790M/C797S signalling |
|
| DCC1708 | Ddd00015314 | Novel activator of the GUS reporter activity, specific increasing in stumpy reporter gene expression |
|
| DCC1709 | Ddd01035881 | Novel transmission blocker of antimalarials, targeting male gametes |
|
| DCC1710 | Ddd-028 | Potent potential non-opioid, non-cannabinoid analgesic for neuropathic and inflammatory pain |
|
| DCC1711 | Ddd100097 | Potent inhibitor of Trypanosoma brucei N-myristoyltransferase (TbNMT) with markedly improved blood-brain barrier permeability |
|
| DCC1712 | Ddhctp Sodium Salt | Novel potent and broad-spectrum antiviral agent, acting as a chain terminator for viral RNA polymerase |
|
| DCC1713 | Ddo-2117 | Novel potent blocker of mixed lineage leukemia 1 (MLL1)-WDR5 interaction, inhibiting MLL1 complex H3K4 methyltransferase activity |
|
| DCC1714 | Ddo-2213 | Novel Potent and Orally Bioavailable Inhibitor of the WDR5-Mixed Lineage Leukemia 1 (MLL1) Protein-Protein Interaction for the Treatment of MLL Fusion Leukemia |
|
